- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04156412
AXONE-Acute II: Acute Assessment of a Micro Multipolar Lead for Enhanced Cardiac Resynchronisation Therapy (AXONE-Acute-2)
June 26, 2020 updated by: University Hospital, Rouen
Pilot study to evaluate the performance of a lead below 2 French with specific distal shape to deliver efficient LV pacing
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
28
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Frédéric ANSELME, Pr
- Phone Number: 8990 +3323288
- Email: frederic.anselme@chu-rouen.fr
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- Bordeaux University Hospital
-
Contact:
- Philippe RITTER, Pr
-
Clermont-Ferrand, France
- Recruiting
- Clermont-Ferrand University Hospital
-
Contact:
- Frédéric Jean, MD
-
Lille, France
- Recruiting
- Lille University Hospital
-
Contact:
- Didier KLUG, Pr
-
Rennes, France
- Recruiting
- Rennes University Hospital
-
Contact:
- Christophe LECLERCQ, Pr
-
Rouen, France
- Recruiting
- Rouen University Hospital
-
-
-
-
-
Badalona, Spain
- Recruiting
- Hospital Universitari Germans Trias i Pujol
-
Contact:
- Roger VILLUENDAS, MD
-
Valencia, Spain
- Recruiting
- Hospital Universitario y Politécnico La Fe
-
Contact:
- Joaquín OSCA, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patient aged ≥18 years old.
- Patient presenting a CRT-P or CRT-D indication according to the latest ESC guidelines1.
- Primary implant of a CRT device (including upgrade from a single or dual-chamber pacemaker or ICD).
- Signed and dated informed consent.
Exclusion Criteria:
- Class IV of NYHA (ambulatory or not).
- Allergy to contrast media used for imaging during cardiac catheterization.
- Severe Renal Failure (clearance of creatinine according to Modification of diet in renal disease formula (MDRD) < 30ml/mn/m²).
- Previous failure of catheterization of the coronary sinus, or previous failure of left ventricular lead implantation.
- Already included in another clinical study involving intra-cardiac active implantable device, or participation to any other clinical trial in the last 2 weeks.
- Vulnerable patient such as person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision).
- Known pregnancy, breastfeeding or women in childbearing age without an adequate contraceptive method with a known failure rate < 1%.-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Implant test procedure
Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
|
Implant test procedure with new LV quadripolar lead before a standard implantation for Cardiac resynchronisation therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LV Bi-zone pacing success rate
Time Frame: 30 min
|
Percent of patients where the placement of the AXONE lead provides two distant LV pacing vectors matching: Pacing Threshold ≤ 3.5V/0.5ms.
|
30 min
|
LV pacing success rate
Time Frame: 30 min
|
Percent of patients where the placement of the AXONE lead allows at least one LV pacing vectors matching: Pacing Threshold ≤ 3.5V/0.5ms.
|
30 min
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device or Implant testing procedure-related Adverse Events
Time Frame: 1 month post intervention
|
1 month post intervention
|
|
Electrical performance (1)
Time Frame: 30 min
|
LV pacing threshold (Volt)
|
30 min
|
Electrical performance (2)
Time Frame: 30 min
|
LV pacing impedance (Ohm)
|
30 min
|
AXONE Implant Efficiency (1)
Time Frame: 30 min
|
procedure time for successful placement
|
30 min
|
AXONE Implant Efficiency (2)
Time Frame: 30 min
|
fluoroscopic time
|
30 min
|
AXONE Implant Efficiency (3)
Time Frame: 30 min
|
radiation dose
|
30 min
|
AXONE Implant Efficiency (4)
Time Frame: 30 min
|
handling assessment.
|
30 min
|
LV multipoint pacing success
Time Frame: 30 min
|
the placement of the AXONE provides two pacing vectors matching
|
30 min
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 2, 2020
Primary Completion (ANTICIPATED)
October 1, 2020
Study Completion (ANTICIPATED)
October 1, 2020
Study Registration Dates
First Submitted
November 5, 2019
First Submitted That Met QC Criteria
November 6, 2019
First Posted (ACTUAL)
November 7, 2019
Study Record Updates
Last Update Posted (ACTUAL)
June 29, 2020
Last Update Submitted That Met QC Criteria
June 26, 2020
Last Verified
June 1, 2020
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2019/127/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Resynchronisation Therapy
-
University Hospital, RouenMicroPort CRMCompletedCardiac Resynchronisation TherapyFrance
-
National University Heart Centre, SingaporeRecruitingHeart Failure | Cardiac Resynchronisation TherapySingapore
-
Hasselt UniversityRecruitingHeart Failure | Telemedicine | Cardiac Resynchronisation TherapyBelgium
-
Charite University, Berlin, GermanyUnknownHeart Failure | Sudden Cardiac Death | Cardiac Resynchronisation TherapyGermany
-
University of DundeeCompletedHeart Failure | Cardiac Resynchronisation PacemakersUnited Kingdom
-
LivaNovaWithdrawnSleep Breathing Disorders in the Responders to Cardiac Resynchronisation Therapy (CRT)Spain, Italy
-
Biotronik SE & Co. KGCompletedCardiac Resynchronization Therapy | Pacemaker TherapyGermany, Austria, Spain, Switzerland
-
EBR Systems, Inc.Active, not recruitingCardiac Resynchronization TherapyDenmark, Germany, Switzerland
-
Heart and Diabetes Center North-Rhine WestfaliaTerminatedCardiac Resynchronization TherapyGermany
-
StereotaxisTerminatedCardiac Resynchronization TherapyUnited States
Clinical Trials on Implant test procedure
-
University Hospital, RouenMicroPort CRMCompletedCardiac Resynchronisation TherapyFrance
-
Boston Scientific CorporationRecruitingCardiac DiseaseFrance, Spain, Italy, Belgium, Germany, Greece, Israel, United Kingdom, Ireland
-
University Health Network, TorontoWomen's College Hospital; Canadian Breast Cancer Foundation; Vancouver General... and other collaboratorsCompleted
-
Neurotech PharmaceuticalsThe Emmes Company, LLC; The Lowy Medical Research Institute LimitedCompletedMacular Telangiectasia Type 2United States, Australia
-
Harvard Medical School (HMS and HSDM)CompletedPartial Edentulism | Atrophy of Edentulous Alveolar RidgeUnited States
-
NYU Langone HealthNot yet recruiting
-
Neurotech PharmaceuticalsCompletedMacular DegenerationUnited States
-
Recep Tayyip Erdogan University Training and Research...Completed
-
Ain Shams UniversityCompletedGlaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Secondary